July 24, 2012 / 5:58 AM / 5 years ago

Galapagos identifies possible new osteoarthritis drug

BRUSSELS (Reuters) - Belgian drug developer Galapagos is in line for an undisclosed milestone payment after identifying a possible oral treatment for osteoarthritis as part of its collaboration with France’s Servier, it said on Tuesday.

“This achievement also marks the third alliance with a different pharma partner in which Galapagos has identified a pre-clinical candidate,” Onno van de Stolpe, Chief Executive Officer of Galapagos, said in a statement.

Reporting By Ben Deighton

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below